Modern Medicine Cases

A tale of two state boards
A tale of two state boardsEvery summer I think about the most recent brigade of freshly minted ODs who have survived four years of optometric boot camp and a challenging gauntlet of National Board Exams. I picture students charging forth across the “no-man’s land” of changing healthcare landscape, lugging their backpacks full of six-figure student debt. My “tale of two state boards” is dedicated to these young comrades in arms.
Are you ready for MACRA?  Scorecards can help
Are you ready for MACRA? Scorecards can helpWith Congress attempting to repeal the Affordable Care Act (ACA), and with the president issuing executive actions to roll back portions of the ACA, some in the medical community have been wondering whether the Medicare Access and CHIP Reauthorization Act (MACRA) also faces an uncertain future.
A call for physicians to denounce third parties once and for allI appeal to my fellow physicians, let us denounce with a single voice practices by third parties.
10 things physicians need to know about MACRA in 2018
10 things physicians need to know about MACRA in 2018CMS adds cost to MIPS score, exempts more physicians in rules for Quality Payment Program next year.
How generic cyclosporine might affect optometry
How generic cyclosporine might affect optometryI foresee every dry eye script I write to be “changed” to generic cyclosporine. This means optometrists will be straddled with more burdensome prior authorizations and delays for the patients.
How I am embracing the medical model in optometry
How I am embracing the medical model in optometryAs we continue to grow as a profession, remember we are treating the whole patient, not just the eye alone. Incorporating lab work and imaging into your comprehensive eye care will improve patient outcomes and continue to grow your practice.
Steroid and NSAID combination prevents macular oedema after cataractsA combination of a topical corticosteroid and a nonsteroidal anti-inflammatory drug (NSAID) is more effective than either one alone in reducing the risk of cystoid macular oedema (CME) after cataract surgery in nondiabetic patients, researchers say.
The OD’s role with new diabetes drugsIt is important for eyecare providers to be familiar with these new drugs and findings. We often see patients with diabetes, metabolic syndrome, and high CV risk, and we are in a position to help counsel our patients about new treatments—and even suggest that appropriate patients have conversations with their primary-care physicians, endocrinologists and cardiologists.
Femtosecond advances help ODs, patientsOur patients have numerous choices regarding advanced technology and eye care. Advances range from how patients check in for an appointment to what tools a surgeon uses to dissect tissue. They all have their benefits, and all come at a cost.
The dangers of starting and stopping glaucoma treatmentThe notion of patients not coming in as advised for eye examinations can be troubling. For example, when a patient has an eye disease as potentially significant as glaucoma and chooses to ignore its presence, there is cause for concern on the part of the doctor.